BDR PHARMACEUTICALS

BDR Pharmaceuticals introduces prostate cancer treatment drug in oral solution form

"Changing how we treat prostate cancer, BDENZA oral solution brings a mix of benefits to make things better for patients. It gives a strong 160 mg dose in just one small 5 ml serving, so there's less hassle associated with lots of pills," BDR Pharmaceuticals Director, Technical Formulation, Aravind Badiger, said.

More in BDR PHARMACEUTICALS

BDR Pharma launches generic cancer drug in India

The capsules are used for the treatment of differentiated thyroid cancer, advanced liver cancer, and advanced kidney cancer, BDR Pharma said in a statement.
BDR Pharma to launch 400mg Favipiravir tablets for treating coronavirus patients in India

The company had received approval from the Drugs Controller General of India (DCGI) to manufacture Favipiravir to treat patients with mild to moderate COVID-19 symptoms under the brand name BDFAVI, according to the statement.
BDR in pact to make Gilead drug for Cipla

In late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangement with Gilead. The Mumbai-based company has now signed a contract to make the drug for Cipla, which is one of the licensed companies.
Delhi High Court upholds BMS’ patent for cancer drug Dasatinib

The Indian Patent Office had in 2013 rejected the company’s demand for a compulsory licence as it did not follow the procedures for obtaining a voluntary licence.